Table 4 The clinical characteristics of the patients that did RT and did not do RT in different risk stratifications
Low risk | Intermediate risk | High risk | |||||||
|---|---|---|---|---|---|---|---|---|---|
Characteristic | non-LRRT | LRRT | P value | non-LRRT | LRRT | P value | non-LRRT | LRRT | P value |
Age (years) | |||||||||
≤ 47 | 15 (44.1%) | 69 (52.3%) | 0.445 | 20 (41.7%) | 42 (46.7%) | 0.595 | 52 (49.5%) | 48 (53.5%) | 0.567 |
> 47 | 19 (55.9%) | 63 (47.7%) | 28 (58.3%) | 48 (53.3%) | 53 (50.5%) | 41 (46.1%) | |||
Gender | |||||||||
Male | 28 (82.4%) | 110 (83.3%) | 1.000 | 34 (70.8%) | 75 (83.3%) | 0.124 | 93 (88.6%) | 74 (83.1%) | 0.304 |
Female | 6 (17.6%) | 22 (16.7%) | 14 (29.2%) | 15 (16.7%) | 12 (11.4%) | 15 (16.9%) | |||
Smoking | |||||||||
No smoking | 22 (64.7%) | 70 (53.0%) | 0.250 | 28 (58.3%) | 53 (58.9%) | 1.000 | 59 (56.2%) | 46 (51.7%) | 0.565 |
Smoking | 12 (35.3%) | 62 (47.0%) | 20 (41.7%) | 37 (41.1%) | 46 (43.8%) | 43 (48.3%) | |||
Family history | |||||||||
No | 31 (91.2%) | 113 (85.6%) | 0.425 | 44 (91.7%) | 83 (92.2%) | 1.000 | 95 (90.5%) | 81 (91.0%) | 1.000 |
Yes | 3 (8.8%) | 19 (14.4%) | 4 (8.3%) | 7 (7.8%) | 10 (9.5%) | 8 (9.0%) | |||
T stage # | |||||||||
T1-T2 | 4 (11.8%) | 24 (18.2%) | 0.451 | 9 (18.8%) | 17 (18.9%) | 1.000 | 16 (15.2%) | 13 (14.6%) | 1.000 |
T3-T4 | 30 (88.2%) | 108 (81.8%) | 39 (81.3%) | 73 (81.1%) | 89 (84.8%) | 76 (85.4%) | |||
N stage # | |||||||||
N0-N1 | 9 (26.5%) | 35 (26.5) | 1.000 | 6 (12.5%) | 18 (20.0%) | 0.348 | 15 (14.3%) | 20 (22.5%) | 0.189 |
N2-N3 | 25 (73.5%) | 97 (73.5%) | 42 (87.5%) | 72 (80.0%) | 90 (85.7%) | 69 (77.5%) | |||
No. of metastatic organ | |||||||||
1 | 34 (100.0%) | 132 (100.0%) | – | 48 (100.0%) | 90 (100.0%) | – | 34 (32.4) | 37 (41.6%) | 0.232 |
> 1 | – | – | – | – | 71 (67.6%) | 52 (58.4%) | |||
No. of metastatic tumor number | |||||||||
≤ 5 | 34 (100.0%) | 132 (100.0%) | – | 48 (100.0%) | 90 (100.0%) | – | 15 (14.3%) | 19 (21.3%) | 0.256 |
> 5 | – | – | – | – | 90 (85.7%) | 70 (78.7%) | |||
EBV-DNA (Copies/ml) | |||||||||
≤ 25,000 | 34 (100.0%) | 132 (100.0%) | – | – | – | – | 25 (23.8%) | 23 (25.8%) | 0.868 |
> 25,000 | – | – | 48 (100.0%) | 90 (100.0%) | 80 (76.2%) | 66 (74.2%) | |||
Chemotherapy regimens | |||||||||
TPF | 7 (20.6%) | 36 (27.3%) | < 0.001 | 11 (22.9%) | 26 (28.9%) | 0.336 | 22 (21.0%) | 26 (29.2%) | 0.004 |
TP | 5 (14.7%) | 36 (27.3%) | 10 (20.8%) | 20 (22.2%) | 21 (20.0%) | 29 (32.6%) | |||
PF | 15 (44.1%) | 27 (20.5%) | 10 (20.8%) | 26 (28.9%) | 33 (31.4%) | 18 (20.2%) | |||
GP | 5 (14.7%) | 3 (2.3%) | 4 (8.3%) | 6 (6.7%) | 9 (8.6%) | 0 (0.0%) | |||
Others | 2 (5.9%) | 30 (22.7%) | 13 (27.1%) | 12 (13.3%) | 20 (19.0%) | 16 (18.0%) | |||